Skip to content

Establishment and Application Research of Early Lung Cancer Prognosis Grading System Based on Machine Learning and New Pathological Features

Establishment and Application Research of Early Lung Cancer Prognosis Grading System Based on Machine Learning and New Pathological Features

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037045
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:Clinical outcome
Index test:A&#32
of&#32
early&#32
lung&#32
cancer&#32
system&#32
based&#32
on&#32
machine&#32
learning&#32
technology&#32
and&#32

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The age of the patient is 18 to 80 years; (2) Single lung lesion; (3) Complete excision after surgery; (4) Pathologically diagnosed as lung adenocarcinoma; (5) Subjects voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion criteria: (1) Pathologically confirmed non-primary lung adenocarcinoma; (2) A history of tumor or other malignant tumors at the same time; (3) Pregnant or lactating women; (4) Those suffering from hypertension who cannot fall within the normal range by antihypertensive drug treatment (systolic blood pressure>140 mmHg, diastolic blood pressure > 90 mmHg), suffering from myocardial ischemia or myocardial infarction or arrhythmia (including QT interval >= 440 ms) and grade I cardiac insufficiency; (5) There are multiple factors that affect surgery (such as moderate to severe lung function abnormalities, coagulation dysfunction, immune system diseases, etc.); (6) Long-term unhealed wounds or fractures; (7) Arterial/venous thrombotic events that occurred within 6 months before the consultation, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism; (8) Those who have a history of psychotropic drug abuse and cannot be quit or have mental disorders; (9) Participated in other clinical trials within 3 months; (10) Have used anti-tumor therapy drugs (including Chinese medicine).

Design outcomes

Primary

MeasureTime frame
prognosis;SEN, SPE, ACC, AUC of ROC, PPV, NPV, etc.;

Countries

China

Contacts

Public ContactChenyang Dai

Shanghai Pulmonary Hospital

daichenyang@tongji.edu.cn+86 13764548980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026